valproic acid has been researched along with Neurodegenerative Diseases in 11 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Kainic acid (KA) induced seizure, a reliable model of TLE, triggers epileptogenic events resulting from initial neuronal death and ensuing recurring seizures." | 3.80 | Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice. ( Bhowmik, M; Saini, N; Vohora, D, 2014) |
| "Quetiapine combined with sodium valproate is an effective and more suitable drug treatment for Alzheimer's disease." | 1.72 | Quetiapine Combined with Sodium Valproate in Patients with Alzheimer's Disease with Mental and Behavioral Symptoms Efficacy Observation. ( Fu, K; He, X; Liu, W; Xu, J; Xu, P; Zhang, Z, 2022) |
| "Treatment with rosiglitazone (5, 10 mg/kg) and VPA (100, 200 mg/kg) for 21 days significantly attenuated these behavioral, biochemical, and cellular alterations as compared to control (QA 200 nmol) group." | 1.40 | Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways. ( Chaudhary, T; Kumar, A; Mishra, J, 2014) |
| "At 14 years after smoke inhalation injury, he had persistent cognitive impairment." | 1.38 | Progressive neuropsychiatric and brain abnormalities after smoke inhalation. ( Tobe, E, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Z | 1 |
| Xu, J | 1 |
| Xu, P | 1 |
| Liu, W | 1 |
| He, X | 1 |
| Fu, K | 1 |
| Ghasemi-Kasman, M | 1 |
| Baharvand, H | 1 |
| Javan, M | 1 |
| Mishra, J | 1 |
| Chaudhary, T | 1 |
| Kumar, A | 1 |
| Bhowmik, M | 1 |
| Saini, N | 1 |
| Vohora, D | 1 |
| González-Polo, RA | 1 |
| Pizarro-Estrella, E | 1 |
| Yakhine-Diop, SM | 1 |
| Rodríguez-Arribas, M | 1 |
| Gómez-Sánchez, R | 1 |
| Pedro, JM | 1 |
| Fuentes, JM | 1 |
| Takamatsu, G | 1 |
| Katagiri, C | 1 |
| Tomoyuki, T | 1 |
| Shimizu-Okabe, C | 1 |
| Nakamura, W | 1 |
| Nakamura-Higa, M | 1 |
| Hayakawa, T | 1 |
| Wakabayashi, S | 1 |
| Kondo, T | 1 |
| Takayama, C | 1 |
| Matsushita, M | 1 |
| Nalivaeva, NN | 1 |
| Belyaev, ND | 1 |
| Turner, AJ | 1 |
| Monti, B | 1 |
| Polazzi, E | 1 |
| Contestabile, A | 1 |
| Lauterbach, EC | 1 |
| Victoroff, J | 1 |
| Coburn, KL | 1 |
| Shillcutt, SD | 1 |
| Doonan, SM | 1 |
| Mendez, MF | 1 |
| Tobe, E | 1 |
| Fukunaga, K | 1 |
| Shioda, N | 1 |
| Morioka, M | 1 |
| Han, F | 1 |
4 reviews available for valproic acid and Neurodegenerative Diseases
| Article | Year |
|---|---|
Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Topics: Animals; Autophagy; Disease Models, Animal; Food; Humans; Isothiocyanates; Lithium; Neurodegenerativ | 2015 |
Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection.
Topics: Chromatin Assembly and Disassembly; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Dea | 2009 |
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzo | 2010 |
[Novel therapeutic strategy for neurogenesis in the neurodegenerative disorders].
Topics: Animals; Cognition; Donepezil; Drug Design; Extracellular Signal-Regulated MAP Kinases; Hippocampus; | 2008 |
7 other studies available for valproic acid and Neurodegenerative Diseases
| Article | Year |
|---|---|
Quetiapine Combined with Sodium Valproate in Patients with Alzheimer's Disease with Mental and Behavioral Symptoms Efficacy Observation.
Topics: Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Dibenzothiazepines; Humans; Neurodegen | 2022 |
Enhanced neurogenesis in degenerated hippocampi following pretreatment with miR-302/367 expressing lentiviral vector in mice.
Topics: Animals; Hippocampus; Kainic Acid; Lentivirus; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Neurodegen | 2017 |
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; | 2014 |
Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice.
Topics: Animals; Anticonvulsants; Benzofurans; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2014 |
Tescalcin is a potential target of class I histone deacetylase inhibitors in neurons.
Topics: Animals; Calcineurin; Calcium; Calcium-Binding Proteins; Cluster Analysis; Epigenesis, Genetic; Gene | 2017 |
Sodium valproate: an old drug with new roles.
Topics: Animals; Anticonvulsants; Histone Deacetylase Inhibitors; Humans; Neurodegenerative Diseases; Neurop | 2009 |
Progressive neuropsychiatric and brain abnormalities after smoke inhalation.
Topics: Activities of Daily Living; Brain; Cognition Disorders; Depressive Disorder, Major; DNA Damage; Fluo | 2012 |